A potential treatment for listeriosis has been found to be promising in Praedicare's hollow fiber preclinical model of the disease, caused by the...
WASHINGTON, June 8, 2021 /PRNewswire/ -- The Antimicrobials Working Group (AWG) announced today the addition of Crestone, Inc. (Crestone) to its coalition of companies with the mission to combat drug resistant infections and spur life-saving innovations. This new addition brings AWG's membership to 12 antimicrobial drug companies.
BOULDER, Colo.--(BUSINESS WIRE)-- Crestone, Inc. today announced the first patient has been enrolled in a Phase 2 clinical trial of CRS3123 for the treatment of Clostridioides difficile infection (CDI). CRS3123 is a novel small molecule antibiotic drug candidate that has demonstrated narrow spectrum and minimal disruption of normal gut microbiota in preclinical and Phase 1 studies. The company also announced the U.S. Food and Drug Administration (FDA) has granted Qualified Infectious Disease Product (QIDP) designation and Fast Track designation to CRS3123 for the treatment of CDI.
BOULDER, Colo.--(BUSINESS WIRE)--Crestone, Inc. today announced a contract award from the National Institutes of Health for the advancement of its antibiotic candidate CRS0540 to treat infections caused by drug-resistant Gram-positive bacteria.
LONDON, April 27, 2020 /PRNewswire/ -- COMPASS Pathways, a mental health care company, announced today that it has completed a successful $80m Series B investment round. This funding will expand upon COMPASS's lead programme in psilocybin therapy for treatment-resistant depression, supporting research into additional indications for psilocybin therapy, advancing the company's preclinical pipeline, developing digital technologies, and establishing new academic and clinical research partnerships.
BOULDER, Colo.--(BUSINESS WIRE)--Crestone, Inc. today announced an award from the Cystic Fibrosis Foundation (CFF) for the preclinical development of its antibiotic lead series to treat nontuberculous mycobacteria (NTM) infections, focusing on M. abscessus.
Crestone, Inc., today announced a Contract Award from the National Institutes of Health focused on the Phase 2 clinical development of its small molecule drug candidate, CRS3123, for the treatment of Clostridioides difficile infections (CDI). Under this contract, the safety and efficacy of CRS3123 will be evaluated for the first time in patients with CDI.